. Author manuscript; available in PMC: 2015 Aug 1.

Published in final edited form as: J Pharm Sci. 2014 Jun 19;103(8):2520–2529. doi: 10.1002/jps.24046

Table 5. Analysis of early (0-8 h) versus late (8-168 h) plasma drug exposure for primates subcutaneously administered with anti-HIV nanoparticles containing three drugs with different incorporation efficiencies.

Drug	Drug incorporation (% total)	AUC (ng•h/mL) ^a			AUC _fraction (% total) ^b

		0-8 h	8-168 h	0-168 h	0-8 h	8-168 h
Atazanavir (ATV)	85.5 ± 8.2	24.3	491.1	515.4	4.7%	95.3%
Ritonavir (RTV)	85.1 ± 7.1	339.1	1,390.3	1,729.4	19.6%	80.4%
Tenofovir (TFV)	6.1 ± 0.8	23,214.8	868,653.6	891,868.3	2.6%	97.4%

The average AUC for the two primates (M11016 and M10088) at indicated time-spans (0-8 h, 8-168 h, and 0-168 h) in units of ng•h/mL.

AUC _fraction for early (0-8 h) and late (8-168 h) are compared with 0-168 h total plasma exposure. The data were expressed as % AUC for each drug.